A vitamin D receptor antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

MeTC7

Item No. 37338

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2-bromo-acetic acid, (6S,8aR,8bR,10aR,11R,13aR)-11-[(1R)-1,5-dimethylhexyl]-2,3,5,6,7,8,8a,8b,10,10a,11,12,13,13a-tetradecahydro-2,8a,10a-trimethyl-1,3-dioxo-4a,13b-etheno-1H,9H-benzo[c]cyclopenta[h][1,2,4]triazolo[1,2-a]cinnolin-6-yl ester
CAS Number
1817841-22-7
Molecular Formula
C32H48BrN3O4
Formula Weight
618.7
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
Ethanol: 1 mg/ml
SMILES
C[C@@]12[C@](C=C[C@@]34C2CC[C@@]5(C)[C@@]3([H])CC[C@]5([H])[C@@H](CCCC(C)C)C)(N6C(N(C)C(N64)=O)=O)C[C@@H](OC(CBr)=O)CC1
InChi Code
InChI=1S/C32H48BrN3O4/c1-20(2)8-7-9-21(3)23-10-11-24-29(23,4)14-13-25-30(5)15-12-22(40-26(37)19-33)18-31(30)16-17-32(24,25)36-28(39)34(6)27(38)35(31)36/h16-17,20-25H,7-15,18-19H2,1-6H3/t21-,22+,23-,24-,25?,29-,30-,31-,32+/m1/s1
InChi Key
LBFDLJSQMPCWKK-RBRUHCLLSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $42

    Add

    5 mg

    $185

    Add

    10 mg

    $327

    Add
    Cayman Chemical
    Visit Our Lipid Nanoparticle Resource Center for Additional Tools & Resources
    EXPLORE NOW
    Product Description

    MeTC7 is a vitamin D receptor (VDR) antagonist (IC50 = 2.9 µM in a fluorescence polarization assay).1 It inhibits VDR transactivation in HEK293 cells (IC50 = 20.8 µM). It decreases the viability of OVCAR-8, OV-2008, SKOV3, Caov-3, and IGROV-1 ovarian cancer cells in a concentration-dependent manner. MeTC7 (250 nM) reduces retinoid X receptor α (RXRα) and importin-4 protein levels in OV-2008 cells. It decreases programmed cell death 1 ligand 1 (PD-L1) levels in primary human acute myeloid leukemia (AML) cells when used at a concentration of 500 nM.2 MeTC7 (10 mg/kg) reduces tumor growth in an SH-SY5Y neuroblastoma mouse xenograft model.1 Lipid nanoparticles (LNPs) containing MeTC7 selectively localize to the pancreas in mice.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Khazan, N., Kim, K.K., Hansen, J.N., et al. Identification of a vitamin-D receptor antagonist, MeTC7, which inhibits the growth of xenograft and transgenic tumors in vivo. J. Med. Chem. 65(8), 6039-6055 (2022).

    2. Khazan, N., Quarato, E.R., Singh, N.A., et al. Vitamin D receptor antagonist MeTC7 inhibits PD-L1. Cancers (Basel) 15(13), 3432 (2023).

    3. Isaac, I., Patel, L., Tran, N., et al. Reengineering endogenous targeting lipid nanoparticles (ENDO) for systemic delivery of mRNA to pancreas. Adv. Mater. 37(40), e2507657 (2025).